首页 > 最新文献

Therapeutic delivery最新文献

英文 中文
Artemisinin emulgel ameliorates cartilage degradation in knee osteoarthritis: in vitro and in vivo studies. 青蒿素凝胶改善膝关节骨关节炎软骨退化:体外和体内研究
IF 3 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-06 DOI: 10.1080/20415990.2024.2418281
Samiksha Thote, Atul Mourya, Shristi Arya, Hoshiyar Singh, Prashanth Kumar, Santosh Kumar Guru, Jitender Madan

Aim: Laboratory scale-up of artemisinin-loaded emulgel (ART-emulgel) was carried out and characterized for therapeutic performance in osteoarthritis (OA).Materials & methods: The solubility of ART in various oils, surfactants and co-surfactants were screened for construction of pseudo ternary phase diagram (TPD), followed by scale-up of artemisinin loaded nanoemulsion (ART-NE). ART-NE was amalgamated with Carbopol Ultrez 10-NF to prepare ART-emulgel that was later characterized in vitro and in vivo to analyze therapeutic efficacy in monosodium-iodoacetate (MIA) induced knee OA.Results: The droplet diameter of ART-NE was estimated to be 104.3 ± 2.593 nm with a polydispersity index of 0.245 ± 0.019 in addition to ζ-potential of 0.434 ± 0.028 mV. Steady-state flux and permeability coefficient for ART-emulgel were estimated to be 0.651 ± 0.031 µg.cm2/h and 0.245 ± 0.011 cm/h, respectively. ART-emulgel demonstrated 43.18% reduction in COX-2 level; 52.28% drop in IL-1β, and 88.78% alleviation of Tumor Necrosis Factor-α (TNF-α) level when compared with monosodium-iodoacetate induced OA rats. ART-emulgel and injectable ART (intra-articular; I.A) portrayed minor synovial erosion compared with blank and diclofenac emulgel. Histopathological evidences indicated restoration of cartilage integrity followed by reduction of OARSI scores in ART-emulgel when compared with disease control animals.Conclusion: ART-emulgel is a potential dosage form for translating into a clinically viable product for the management of OA.

目的:对青蒿素载体凝胶(ART-emulgel)进行实验室放大,并对其在骨关节炎(OA)中的治疗性能进行表征:筛选了青蒿素在各种油类、表面活性剂和辅助表面活性剂中的溶解度,构建了伪三元相图(TPD),随后对青蒿素负载纳米乳液(ART-NE)进行了放大。ART-NE与Carbopol Ultrez 10-NF混合制备成ART-emulgel,然后对其进行体外和体内表征,分析其对碘乙酸钠(MIA)诱导的膝关节OA的疗效:ART-NE 的液滴直径估计为 104.3 ± 2.593 nm,多分散指数为 0.245 ± 0.019,ζ电位为 0.434 ± 0.028 mV。估计 ART-emulgel 的稳态通量和渗透系数分别为 0.651 ± 0.031 µg.cm2/h 和 0.245 ± 0.011 cm/h。与碘乙酸钠诱导的 OA 大鼠相比,ART 胶体可降低 COX-2 水平 43.18%;IL-1β 降低 52.28%;肿瘤坏死因子-α(TNF-α)水平降低 88.78%。与空白和双氯芬酸凝胶相比,ART凝胶和注射用ART(关节内;I.A)的滑膜侵蚀程度较轻。组织病理学证据表明,与疾病对照组动物相比,ART-栓剂恢复了软骨的完整性,OARSI评分也随之降低:ART-emulgel 是一种潜在的剂型,可转化为临床上可行的产品用于治疗 OA。
{"title":"Artemisinin emulgel ameliorates cartilage degradation in knee osteoarthritis: <i>in vitro</i> and <i>in vivo</i> studies.","authors":"Samiksha Thote, Atul Mourya, Shristi Arya, Hoshiyar Singh, Prashanth Kumar, Santosh Kumar Guru, Jitender Madan","doi":"10.1080/20415990.2024.2418281","DOIUrl":"https://doi.org/10.1080/20415990.2024.2418281","url":null,"abstract":"<p><p><b>Aim:</b> Laboratory scale-up of artemisinin-loaded emulgel (ART-emulgel) was carried out and characterized for therapeutic performance in osteoarthritis (OA).<b>Materials & methods:</b> The solubility of ART in various oils, surfactants and co-surfactants were screened for construction of pseudo ternary phase diagram (TPD), followed by scale-up of artemisinin loaded nanoemulsion (ART-NE). ART-NE was amalgamated with Carbopol Ultrez 10-NF to prepare ART-emulgel that was later characterized <i>in vitro</i> and <i>in vivo</i> to analyze therapeutic efficacy in monosodium-iodoacetate (MIA) induced knee OA.<b>Results:</b> The droplet diameter of ART-NE was estimated to be 104.3 ± 2.593 nm with a polydispersity index of 0.245 ± 0.019 in addition to ζ-potential of 0.434 ± 0.028 mV. Steady-state flux and permeability coefficient for ART-emulgel were estimated to be 0.651 ± 0.031 µg.cm<sup>2</sup>/h and 0.245 ± 0.011 cm/h, respectively. ART-emulgel demonstrated 43.18% reduction in COX-2 level; 52.28% drop in IL-1β, and 88.78% alleviation of Tumor Necrosis Factor-α (TNF-α) level when compared with monosodium-iodoacetate induced OA rats. ART-emulgel and injectable ART (intra-articular; I.A) portrayed minor synovial erosion compared with blank and diclofenac emulgel. Histopathological evidences indicated restoration of cartilage integrity followed by reduction of OARSI scores in ART-emulgel when compared with disease control animals.<b>Conclusion:</b> ART-emulgel is a potential dosage form for translating into a clinically viable product for the management of OA.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive insights into glioblastoma multiforme: drug delivery challenges and multimodal treatment strategies. 全面了解多形性胶质母细胞瘤:给药挑战和多模式治疗策略。
IF 3 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-24 DOI: 10.1080/20415990.2024.2415281
Ashish Dhiman, Dhwani Rana, Derajram Benival, Kalpna Garkhal

Glioblastoma multiforme (GBM) is one of the most common and malignant brain tumors, with a high prevalence in elderly population. Most chemotherapeutic agents fail to reach the tumor site due to various challenges. However, smart nanocarriers have demonstrated excellent drug-loading capabilities, enabling them to cross the blood brain tumor barrier for the GBM treatment. Surface modification of nanocarriers has significantly enhanced their potential for targeting therapeutics. Moreover, recent innovations in drug therapies, such as the incorporation of theranostic agents in nanocarriers and antibody-drug conjugates, have offered newer insights for both diagnosis and treatment. This review focuses on recent advances in new therapeutic interventions for GBM, with an emphasis on the nanotheranostics systems to maximize therapeutic and diagnostic outcomes.

多形性胶质母细胞瘤(GBM)是最常见的恶性脑肿瘤之一,在老年人群中发病率很高。由于面临各种挑战,大多数化疗药物都无法到达肿瘤部位。然而,智能纳米载体已显示出卓越的药物负载能力,使其能够穿过血脑屏障,用于治疗脑胶质瘤。纳米载体的表面改性大大提高了其靶向治疗的潜力。此外,药物疗法的最新创新,如在纳米载体和抗体药物共轭物中加入治疗药物,为诊断和治疗提供了新的思路。本综述将重点介绍 GBM 新疗法干预措施的最新进展,并着重介绍可最大限度提高治疗和诊断效果的纳米治疗系统。
{"title":"Comprehensive insights into glioblastoma multiforme: drug delivery challenges and multimodal treatment strategies.","authors":"Ashish Dhiman, Dhwani Rana, Derajram Benival, Kalpna Garkhal","doi":"10.1080/20415990.2024.2415281","DOIUrl":"https://doi.org/10.1080/20415990.2024.2415281","url":null,"abstract":"<p><p>Glioblastoma multiforme (GBM) is one of the most common and malignant brain tumors, with a high prevalence in elderly population. Most chemotherapeutic agents fail to reach the tumor site due to various challenges. However, smart nanocarriers have demonstrated excellent drug-loading capabilities, enabling them to cross the blood brain tumor barrier for the GBM treatment. Surface modification of nanocarriers has significantly enhanced their potential for targeting therapeutics. Moreover, recent innovations in drug therapies, such as the incorporation of theranostic agents in nanocarriers and antibody-drug conjugates, have offered newer insights for both diagnosis and treatment. This review focuses on recent advances in new therapeutic interventions for GBM, with an emphasis on the nanotheranostics systems to maximize therapeutic and diagnostic outcomes.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142508508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atorvastatin loaded glycerosomal patch as an effective transdermal drug delivery: optimization and evaluation. 阿托伐他汀负载甘油囊贴片作为一种有效的透皮给药:优化与评估。
IF 3 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-21 DOI: 10.1080/20415990.2024.2408218
Pravin Patil, Mrunal Rahangdale, Krutika Sawant

Aim: The study explores glycerosomes as effective vesicular systems for transdermal delivery of atorvastatin (ATO) to overcome drawbacks related to its oral administration.Methodology: The objectives of this study were to formulate, by thin-film hydration method, optimize using definitive screening design and evaluate ATO-loaded glycerosomes (ATOG) which were then incorporated into patch followed by the evaluation of glycerosomes containing different concentration of glycerol.Results & discussion: Vesicle size, Polydispersity index (PDI), zeta potential, entrapment efficiency and loading capacity of spherical ATOG (0-30%w/w) showed 137.3-192d.nm, 0.292-0.403, -3.81 to-6.76mV, 80.03-92.77% and 5.80-6.40%, respectively. In-vitro release study showed sustained release, increased skin permeability and better cell viability than pure drug. ATOG patches showed greater skin permeability than pure drug and ATO-liposomal patches.Conclusion: The study concludes that ATOGs are promising for effective transdermal delivery.

目的:本研究探讨了甘油囊作为阿托伐他汀(ATO)透皮给药的有效囊泡系统,以克服口服给药的相关缺点:本研究的目的是通过薄膜水合法配制、使用确定性筛选设计进行优化并评估负载 ATO 的甘油囊(ATOG),然后将其纳入贴片,接着评估含有不同浓度甘油的甘油囊:球形 ATOG(0-30%w/w)的囊泡大小、多分散指数(PDI)、ZETA电位、夹持效率和负载能力分别为 137.3-192d.nm、0.292-0.403、-3.81-6.76mV、80.03-92.77% 和 5.80-6.40%。体外释放研究显示,与纯药物相比,ATOG 贴片具有持续释放、皮肤渗透性更强和细胞存活率更高的特点。ATOG 贴片的皮肤渗透性高于纯药物和 ATO 脂质体贴片:该研究得出结论,ATOGs 有望实现有效的透皮给药。
{"title":"Atorvastatin loaded glycerosomal patch as an effective transdermal drug delivery: optimization and evaluation.","authors":"Pravin Patil, Mrunal Rahangdale, Krutika Sawant","doi":"10.1080/20415990.2024.2408218","DOIUrl":"https://doi.org/10.1080/20415990.2024.2408218","url":null,"abstract":"<p><p><b>Aim:</b> The study explores glycerosomes as effective vesicular systems for transdermal delivery of atorvastatin (ATO) to overcome drawbacks related to its oral administration.<b>Methodology:</b> The objectives of this study were to formulate, by thin-film hydration method, optimize using definitive screening design and evaluate ATO-loaded glycerosomes (ATOG) which were then incorporated into patch followed by the evaluation of glycerosomes containing different concentration of glycerol.<b>Results & discussion:</b> Vesicle size, Polydispersity index (PDI), zeta potential, entrapment efficiency and loading capacity of spherical ATOG (0-30%w/w) showed 137.3-192d.nm, 0.292-0.403, -3.81 to-6.76mV, 80.03-92.77% and 5.80-6.40%, respectively. <i>In-vitro</i> release study showed sustained release, increased skin permeability and better cell viability than pure drug. ATOG patches showed greater skin permeability than pure drug and ATO-liposomal patches.<b>Conclusion:</b> The study concludes that ATOGs are promising for effective transdermal delivery.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Industry Update: the latest developments in the field of therapeutic delivery, July 2024. 行业最新动态:2024 年 7 月治疗给药领域的最新发展。
IF 3 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-18 DOI: 10.1080/20415990.2024.2414732
Peter Timmins
{"title":"Industry Update: the latest developments in the field of therapeutic delivery, July 2024.","authors":"Peter Timmins","doi":"10.1080/20415990.2024.2414732","DOIUrl":"https://doi.org/10.1080/20415990.2024.2414732","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Strategies for transportation of peptides across the skin for treatment of multiple diseases. 跨皮肤运输肽以治疗多种疾病的策略。
IF 3 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-16 DOI: 10.1080/20415990.2024.2411943
Janhavi Bhavsar, Kaustubh Kasture, Bhagyashree V Salvi, Pravin Shende

An established view in genetic engineering dictates an increase in the discovery of therapeutic peptides to enable the treatment of multiple diseases. The use of hypodermic needle for delivery of proteins and peptides occurs due to the hydrophilic nature, sensitivity toward proteolytic enzymes and high molecular weight. The non-invasive nature of the transdermal delivery technique offers multiple advantages over the invasive route to release drugs directly into the systemic circulation to enhance bioavailability, better patient compliance, reduced toxicity and local irritability. The transdermal route seems highly desirable from the pharmaco-therapeutic and patient compliance point of view, however, the lipophilic barrier of skin restricts the application. The use of several techniques like electrical methods (iontophoresis, sonophoresis etc.), chemical penetration enhancers (e.g. protease inhibitors, penetration enhancers, etc.) and nanocarriers (dendrimers, lipid nanocapsules, etc.) are utilized to improve the passage of drug molecules across the biomembranes. Additionally, such clinical interventions facilitate the physicochemical characteristics of peptides, to enable effective preservation, conveyance and release of therapeutic agents. Moreover, strategies ensure the attainment of the intended targets and enhance treatment outcomes for multiple diseases. This review article focuses on the techniques of peptide transportation across the skin to advance the delivery approaches and therapeutic efficiency.

基因工程的既定观点决定了治疗肽的发现越来越多,从而能够治疗多种疾病。皮下注射针头具有亲水性、对蛋白水解酶的敏感性和高分子量等特点,因此被用于输送蛋白质和肽。与侵入性途径相比,透皮给药技术的非侵入性具有多种优势,可将药物直接释放到全身循环中,从而提高生物利用度,改善患者的依从性,降低毒性和局部刺激性。从药物治疗和患者依从性的角度来看,透皮给药途径似乎非常理想,但皮肤的亲脂屏障限制了其应用。为了改善药物分子穿过生物膜的情况,我们使用了多种技术,如电方法(离子透入疗法、声波透入疗法等)、化学渗透促进剂(如蛋白酶抑制剂、渗透促进剂等)和纳米载体(树枝状聚合物、脂质纳米胶囊等)。此外,这些临床干预措施还有助于改善肽的理化特性,从而有效保存、输送和释放治疗药物。此外,这些策略还能确保达到预期目标,提高多种疾病的治疗效果。这篇综述文章重点介绍了多肽在皮肤上的传输技术,以推进传输方法和治疗效率。
{"title":"Strategies for transportation of peptides across the skin for treatment of multiple diseases.","authors":"Janhavi Bhavsar, Kaustubh Kasture, Bhagyashree V Salvi, Pravin Shende","doi":"10.1080/20415990.2024.2411943","DOIUrl":"https://doi.org/10.1080/20415990.2024.2411943","url":null,"abstract":"<p><p>An established view in genetic engineering dictates an increase in the discovery of therapeutic peptides to enable the treatment of multiple diseases. The use of hypodermic needle for delivery of proteins and peptides occurs due to the hydrophilic nature, sensitivity toward proteolytic enzymes and high molecular weight. The non-invasive nature of the transdermal delivery technique offers multiple advantages over the invasive route to release drugs directly into the systemic circulation to enhance bioavailability, better patient compliance, reduced toxicity and local irritability. The transdermal route seems highly desirable from the pharmaco-therapeutic and patient compliance point of view, however, the lipophilic barrier of skin restricts the application. The use of several techniques like electrical methods (iontophoresis, sonophoresis etc.), chemical penetration enhancers (e.g. protease inhibitors, penetration enhancers, etc.) and nanocarriers (dendrimers, lipid nanocapsules, etc.) are utilized to improve the passage of drug molecules across the biomembranes. Additionally, such clinical interventions facilitate the physicochemical characteristics of peptides, to enable effective preservation, conveyance and release of therapeutic agents. Moreover, strategies ensure the attainment of the intended targets and enhance treatment outcomes for multiple diseases. This review article focuses on the techniques of peptide transportation across the skin to advance the delivery approaches and therapeutic efficiency.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Industry updates in the field of therapeutic delivery in June 2024. 2024 年 6 月治疗给药领域的行业动态。
IF 3 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-11 DOI: 10.1080/20415990.2024.2408214
Mengistie Diress, Armin Mooranian, Hani Al-Salami
{"title":"Industry updates in the field of therapeutic delivery in June 2024.","authors":"Mengistie Diress, Armin Mooranian, Hani Al-Salami","doi":"10.1080/20415990.2024.2408214","DOIUrl":"https://doi.org/10.1080/20415990.2024.2408214","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142401364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Etodolac utility in osteoarthritis: drug delivery challenges, topical nanotherapeutic strategies and potential synergies. 依托度酸在骨关节炎中的应用:给药挑战、局部纳米治疗策略和潜在的协同作用。
IF 3 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-30 DOI: 10.1080/20415990.2024.2405456
Pavani Gaddala, Shalki Choudhary, Sheshank Sethi, Vaskuri Gs Sainaga Jyothi, Chantibabu Katta, Deepankar Bahuguna, Pankaj Kumar Singh, Manisha Pandey, Jitender Madan

Osteoarthritis (OSA) is a prevalent joint disorder characterized by losing articular cartilage, primarily affecting the hip, knee and spine joints. The impact of OSA offers a major challenge to health systems globally. Therapeutic approaches encompass surgical interventions, non-pharmacological therapies (exercise, rehabilitation, behavioral interventions) and pharmacological treatments. Inflammatory processes within OSA joints are regulated by pro-inflammatory and anti-inflammatory cytokines. Etodolac, a COX-2-selective inhibitor, is the gold standard for OSA management and uniquely does not inhibit gastric prostaglandins. This comprehensive review offers insights into OSA's pathophysiology, genetic factors and biological determinants influencing disease progression. Emphasis is placed on the pivotal role of etodolac in OSA management, supported by both preclinical and clinical evidences in topical drug delivery. Notably, in-silico docking studies suggested potential synergies between etodolac and baicalein, considering ADAMTS-4, COX-2, MMP-3 and MMP-13 as essential therapeutic targets. Integration of artificial neural network (ANN) techniques with nanotechnology approaches emerges as a promising strategy for optimizing and personalizing topical etodolac delivery. Furthermore, the synergistic potential of etodolac and baicalein warrants in-depth exploration. Hence, by embracing cutting-edge technologies like ANN and nanomedicine, the optimization of topical etodolac delivery could guide a new era of OSA treatment.

骨关节炎(OSA)是一种以关节软骨流失为特征的常见关节疾病,主要影响髋关节、膝关节和脊柱关节。OSA 的影响给全球卫生系统带来了重大挑战。治疗方法包括手术干预、非药物疗法(运动、康复、行为干预)和药物疗法。OSA 关节内的炎症过程受促炎症和抗炎症细胞因子的调节。依托度酸是一种 COX-2 选择性抑制剂,是治疗 OSA 的黄金标准,而且不会抑制胃前列腺素。本综述深入探讨了 OSA 的病理生理学、遗传因素和影响疾病进展的生物学决定因素。在局部给药的临床前和临床证据支持下,重点介绍了依托度酸在 OSA 治疗中的关键作用。值得注意的是,在将 ADAMTS-4、COX-2、MMP-3 和 MMP-13 作为基本治疗靶点的同时,硅内对接研究表明依托度酸和黄芩苷之间存在潜在的协同作用。将人工神经网络(ANN)技术与纳米技术方法相结合,是优化和个性化局部依托度酸给药的有效策略。此外,依托度酸和黄芩苷的协同潜力也值得深入探讨。因此,通过采用 ANN 和纳米医学等前沿技术,局部依托度酸给药的优化将引领 OSA 治疗进入一个新时代。
{"title":"Etodolac utility in osteoarthritis: drug delivery challenges, topical nanotherapeutic strategies and potential synergies.","authors":"Pavani Gaddala, Shalki Choudhary, Sheshank Sethi, Vaskuri Gs Sainaga Jyothi, Chantibabu Katta, Deepankar Bahuguna, Pankaj Kumar Singh, Manisha Pandey, Jitender Madan","doi":"10.1080/20415990.2024.2405456","DOIUrl":"https://doi.org/10.1080/20415990.2024.2405456","url":null,"abstract":"<p><p>Osteoarthritis (OSA) is a prevalent joint disorder characterized by losing articular cartilage, primarily affecting the hip, knee and spine joints. The impact of OSA offers a major challenge to health systems globally. Therapeutic approaches encompass surgical interventions, non-pharmacological therapies (exercise, rehabilitation, behavioral interventions) and pharmacological treatments. Inflammatory processes within OSA joints are regulated by pro-inflammatory and anti-inflammatory cytokines. Etodolac, a COX-2-selective inhibitor, is the gold standard for OSA management and uniquely does not inhibit gastric prostaglandins. This comprehensive review offers insights into OSA's pathophysiology, genetic factors and biological determinants influencing disease progression. Emphasis is placed on the pivotal role of etodolac in OSA management, supported by both preclinical and clinical evidences in topical drug delivery. Notably, <i>in</i>-<i>silico</i> docking studies suggested potential synergies between etodolac and baicalein, considering ADAMTS-4, COX-2, MMP-3 and MMP-13 as essential therapeutic targets. Integration of artificial neural network (ANN) techniques with nanotechnology approaches emerges as a promising strategy for optimizing and personalizing topical etodolac delivery. Furthermore, the synergistic potential of etodolac and baicalein warrants in-depth exploration. Hence, by embracing cutting-edge technologies like ANN and nanomedicine, the optimization of topical etodolac delivery could guide a new era of OSA treatment.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanotechnology-driven therapies for neurodegenerative diseases: a comprehensive review. 神经退行性疾病的纳米技术驱动疗法:综述。
IF 3 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-09-19 DOI: 10.1080/20415990.2024.2401307
Jessica López-Espinosa, Peter Park, Morgan Holcomb, Biana Godin, Sonia Villapol

Neurological diseases, characterized by neuroinflammation and neurodegeneration, impose a significant global burden, contributing to substantial morbidity, disability and mortality. A common feature of these disorders, including stroke, traumatic brain injury and Alzheimer's disease, is the impairment of the blood-brain barrier (BBB), a critical structure for maintaining brain homeostasis. The compromised BBB in neurodegenerative conditions poses a significant challenge for effective treatment, as it allows harmful substances to accumulate in the brain. Nanomedicine offers a promising approach to overcoming this barrier, with nanoparticles (NPs) engineered to deliver therapeutic agents directly to affected brain regions. This review explores the classification and design of NPs, divided into organic and inorganic categories and further categorized based on their chemical and physical properties. These characteristics influence the ability of NPs to carry and release therapeutic agents, target specific tissues and ensure appropriate clearance from the body. The review emphasizes the potential of NPs to enhance the diagnosis and treatment of neurodegenerative diseases through targeted delivery, improved drug bioavailability and real-time therapeutic efficacy monitoring. By addressing the challenges of the compromised BBB and targeting inflammatory biomarkers, NPs represent a cutting-edge strategy in managing neurological disorders, promising better patient outcomes.

以神经炎症和神经变性为特征的神经系统疾病给全球造成了沉重负担,导致大量患者发病、残疾和死亡。这些疾病(包括中风、脑外伤和阿尔茨海默病)的一个共同特征是血脑屏障(BBB)受损,而血脑屏障是维持大脑平衡的关键结构。神经退行性疾病中受损的血脑屏障会使有害物质在大脑中积聚,从而对有效治疗构成重大挑战。纳米医学为克服这一障碍提供了一种前景广阔的方法,通过对纳米粒子(NPs)进行设计,可将治疗药物直接输送到受影响的脑区。本综述探讨了 NPs 的分类和设计,分为有机和无机两类,并根据其化学和物理特性作了进一步分类。这些特性影响着 NPs 携带和释放治疗剂、靶向特定组织以及确保适当清除体外的能力。综述强调了 NPs 通过靶向递送、改善药物生物利用度和实时疗效监测来提高神经退行性疾病诊断和治疗水平的潜力。通过应对BBB受损和靶向炎症生物标志物的挑战,NPs代表了一种治疗神经系统疾病的前沿策略,有望为患者带来更好的治疗效果。
{"title":"Nanotechnology-driven therapies for neurodegenerative diseases: a comprehensive review.","authors":"Jessica López-Espinosa, Peter Park, Morgan Holcomb, Biana Godin, Sonia Villapol","doi":"10.1080/20415990.2024.2401307","DOIUrl":"https://doi.org/10.1080/20415990.2024.2401307","url":null,"abstract":"<p><p>Neurological diseases, characterized by neuroinflammation and neurodegeneration, impose a significant global burden, contributing to substantial morbidity, disability and mortality. A common feature of these disorders, including stroke, traumatic brain injury and Alzheimer's disease, is the impairment of the blood-brain barrier (BBB), a critical structure for maintaining brain homeostasis. The compromised BBB in neurodegenerative conditions poses a significant challenge for effective treatment, as it allows harmful substances to accumulate in the brain. Nanomedicine offers a promising approach to overcoming this barrier, with nanoparticles (NPs) engineered to deliver therapeutic agents directly to affected brain regions. This review explores the classification and design of NPs, divided into organic and inorganic categories and further categorized based on their chemical and physical properties. These characteristics influence the ability of NPs to carry and release therapeutic agents, target specific tissues and ensure appropriate clearance from the body. The review emphasizes the potential of NPs to enhance the diagnosis and treatment of neurodegenerative diseases through targeted delivery, improved drug bioavailability and real-time therapeutic efficacy monitoring. By addressing the challenges of the compromised BBB and targeting inflammatory biomarkers, NPs represent a cutting-edge strategy in managing neurological disorders, promising better patient outcomes.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142295997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent updates on ocular disease management with ophthalmic ointments 眼科软膏治疗眼疾的最新进展
IF 4.2 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-06-11 DOI: 10.1080/20415990.2024.2346047
A. C. Bisen, Ayush Dubey, Sristi Agrawal, Arpon Biswas, K. S. Rawat, Saurabh Srivastava, R. Bhatta
{"title":"Recent updates on ocular disease management with ophthalmic ointments","authors":"A. C. Bisen, Ayush Dubey, Sristi Agrawal, Arpon Biswas, K. S. Rawat, Saurabh Srivastava, R. Bhatta","doi":"10.1080/20415990.2024.2346047","DOIUrl":"https://doi.org/10.1080/20415990.2024.2346047","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141359954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fabrication and characterization of cocoa butter-based caffeine fast-melting tablets 以可可脂为基础的咖啡因快速融化片剂的制造和表征
IF 4.2 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-06-11 DOI: 10.1080/20415990.2024.2354115
Ashok Kumar Janakiraman, Joanne Yap, Ramkanth Sundarapandian, Kai Bin Liew, Vetriselvan Subramaniyan, S. Kayarohanam
{"title":"Fabrication and characterization of cocoa butter-based caffeine fast-melting tablets","authors":"Ashok Kumar Janakiraman, Joanne Yap, Ramkanth Sundarapandian, Kai Bin Liew, Vetriselvan Subramaniyan, S. Kayarohanam","doi":"10.1080/20415990.2024.2354115","DOIUrl":"https://doi.org/10.1080/20415990.2024.2354115","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141356766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Therapeutic delivery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1